Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients

被引：11
|
作者：
Ruzzo, A. [1 ]
Canestrari, E. [1 ]
Galluccio, N. [1 ]
Santini, D. [2 ]
Vincenzi, B. [2 ]
Tonini, G. [2 ]
Magnani, M. [1 ]
Graziano, F. [3 ]
机构：
[1] Univ Urbino, Dept Biomol Sci, I-61029 Urbino, Italy
[2] Univ Campus Biomed, Med Oncol Unit, Rome, Italy
[3] Azienda Osped San Salvatore, Dept Oncohematol, Div Oncol, Pesaro, Italy
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷 / 01期
关键词：
CETUXIMAB; BRAF;
D O I：
10.1093/annonc/mdq472
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：234 / U274
页数：2
相关论文
共 50 条
  • [41] The let-7 microRNA binding site variant in the KRAS 3′-UTR is not associated with the risk of head and neck cancer
    Dalay, Nejat
    Demokan, Semra
    Suoglu, Yusufhan
    Yilmazer, Rasim
    Ulusan, Murat
    CANCER RESEARCH, 2014, 74 (19)
  • [42] GENETIC MODULATION OF THE LET-7 MICRO-RNA BINDING TO KRAS 3′-UNTRANSLATED REGION (3′-UTR) IMPACTS ON SURVIVAL OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) WITH UNRESPONSIVE DISEASE TO SALVAGE CETUXIMAB-IRINOTECAN
    Graziano, Francesco
    Canestrari, Emanuele
    Loupakis, Fotios
    Ruzzo, Annamaria
    Santini, Daniele
    Galluccio, Nadia
    Vincenzi, Bruno
    Salvatore, Lisa
    Cremolini, Chiara
    Spoto, Chiara
    Schirripa, Marta
    Catalano, Vincenzo
    D'Emidio, Silvia
    Giordani, Paolo
    Alessandroni, Paolo
    Falcone, Alfredo
    Tonini, Giuseppe
    Magnani, Mauro
    ANNALS OF ONCOLOGY, 2009, 20
  • [43] The Role of the Let-7 microRNA Family as Biomarker Prognostic Indicator Against Breast Cancer
    AL-Aflwky, Ahmed Khidher Hamza
    Shaheed, Orass Madhi
    JOURNAL OF PHARMACEUTICAL NEGATIVE RESULTS, 2022, 13 : 1253 - 1260
  • [44] The role of let-7 regulation by p300 during breast cancer progression
    Yuan, Huijun
    Sharma, Salil
    Bishopric, Nanette
    CANCER RESEARCH, 2009, 69
  • [45] Significance of KRAS Mutation in Patients Receiving mFOLFOX6 with or without Bevacizumab for Metastatic Colorectal Cancer
    Koike, Junichi
    Ushigome, Mitsunori
    Funahashi, Kimihiko
    Shiokawa, Hiroyuki
    Kaneko, Tomoaki
    Arai, Kenichiro
    Matsuda, Satoshi
    Kagami, Satoru
    Suzuki, Takayuki
    Kurihara, Akiharu
    Shimada, Hideaki
    Kaneko, Hironori
    HEPATO-GASTROENTEROLOGY, 2014, 61 (136) : 2222 - 2226
  • [46] Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer
    Ntavatzikos, Anastasios
    Spathis, Aris
    Patapis, Paul
    Machairas, Nikolaos
    Peros, George
    Konstantoudakis, Stefanos
    Leventakou, Danai
    Panayiotides, Ioannis G.
    Karakitsos, Petros
    Koumarianou, Anna
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (32) : 5913 - 5924
  • [47] GENETIC ANALYSIS OF KRAS MUTATION STATUS IN METASTATIC COLORECTAL CANCER PATIENTS
    Zavodna, K.
    Konecny, M.
    Spanik, S.
    Galbavy, S.
    Vizvaryova, M.
    Weismanova, E.
    Kausitz, J.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4015 - 4016
  • [48] KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer
    Radanova, Maria
    Mihaylova, Galya
    St Stoyanov, George
    Draganova, Vyara
    Zlatarov, Aleksandar
    Kolev, Nikola
    Dimitrova, Eleonora
    Conev, Nikolay
    Ivanova, Diana
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (16)
  • [49] Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer
    Anastasios Ntavatzikos
    Aris Spathis
    Paul Patapis
    Nikolaos Machairas
    George Peros
    Stefanos Konstantoudakis
    Danai Leventakou
    Ioannis G Panayiotides
    Petros Karakitsos
    Anna Koumarianou
    World Journal of Gastroenterology, 2017, 23 (32) : 5913 - 5924
  • [50] Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status
    Modest, Dominik P.
    Stintzing, Sebastian
    Laubender, Ruediger P.
    Neumann, Jens
    Jung, Andreas
    Giessen, Clemens
    Haas, Michael
    Aubele, Philipp
    Schulz, Christoph
    Boeck, Stefan
    Stemmler, Hans-Joachim
    Kirchner, Thomas
    Heinemann, Volker
    ANTI-CANCER DRUGS, 2011, 22 (09) : 913 - 918
12345